Antibody treatment for chronic lung disease after stem cell transplant
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests a new antibody medicine called tezelumab for patients who develop a breathing problem called bronchiolitis obliterans syndrome (BOS) after a stem cell transplant. The trial aims to see if this medicine can reduce flare-ups and improve lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You had a stem cell or bone marrow transplant at least 3 years ago.
- You have been diagnosed with bronchiolitis obliterans syndrome (BOS), a lung condition that causes airflow blockage.
- You have had 2 or more moderate to severe flare-ups of your lung problems in the past 12 months.
- You are currently using a long-acting bronchodilator and inhaled corticosteroid for your lungs for at least 3 months.
- Your immunosuppressive medication dose has been stable for the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests nintedanib to slow or improve bronchiolitis obliterans syndrome (BOS), a type of lung scarring, after a hematopoietic stem cell transplant. You may be considered if your breathing tests and scans show BOS, and if active infections and certain health risks are ruled out.
This trial tests tezepelumab, an injected medication, for people with moderate to very severe COPD who still have flare-ups despite using standard inhalers. It may help reduce flare-ups and improve breathing for those with higher eosinophil levels.
This Phase 2 study tests belumosudil to treat or prevent bronchiolitis obliterans (BOS), a lung complication that can happen after a stem cell transplant. If you qualify, you would be checked closely with breathing tests and scans, and watched for safety and whether lung function improves or stays stable.
This study tests a new medication called tezepelumab (given as a shot) to see if it can reduce COPD flare-ups in people with moderate to very severe COPD who have had recent flare-ups despite using inhalers. It may be an option for those with higher levels of eosinophils (a type of white blood cell) in their blood.
This study tests whether the drug LAM-001 can help people who have developed a condition called bronchiolitis obliterans syndrome (BOS) after a double lung transplant. BOS causes a slow decline in lung function, and this trial aims to see if LAM-001 can slow or stop that decline.
This study tests a drug called tezepelumab for people with severe asthma that is not well controlled with current treatments. It aims to see if adding this drug can reduce asthma attacks and improve symptoms.
Hear when a new HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.